CTFA says some cosmetic drugs should be exempt from label order-of-information regs.
This article was originally published in The Tan Sheet
CTFA ADVOCATES "SPECIAL" LABEL REGS FOR COSMETIC DRUGS WITHOUT DOSE LIMITS at a Sept. 29 FDA public hearing on OTC drug labeling. CTFA Associate General Counsel James Skiles stressed that the association "fully supports" the OTC label reform proposal presented by Nonprescription Drug Manufacturers Association VP-Science and Technology William Soller, PhD, at the hearing. However, he maintained that "cosmetic drugs that do not bear dosage limitations" should be exempt from NDMA's order of information for labels, which stipulates that active ingredients should be listed first.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC